Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Obinutuzumab for PCNSL Responders
NCT06175000Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in primary central nervous system lymphoma (PCNSL). Started Mar 2024; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06175000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175000.